GSK is a de-risked, post-demerger biopharma turnaround whose undervalued shares hinge on vaccine durability, HIV portfolio migration, and late-stage pipeline execution.
Overview
GSK has transformed from a diversified healthcare conglomerate into a focused biopharmaceutical company centered on infectious diseases, HIV, oncology, and respiratory/immunology. Following the Haleon demerger, management is targeting more than £40 billion of risk-adjusted annual revenue by 2031. Growth is increasingly driven by Specialty Medicines and Vaccines, with the US as the key profit market. Its moat rests on leading vaccine platforms, long-acting HIV innovation, and improving R&D discipline, positioning GSK as a revitalized pharmaceutical leader with meaningful pipeline optionality.